{
"vaccines" : [{"id" : 0 ,
  "name" : "Inactivated Influenza (IIV)",
  "indication" : "Recommended for all adults with HIV" ,
  "administration":"One <b>IIV</b> dose every year in the fall or winter",
  "contrain":"- Previous severe allergic reaction<br> - Moderate or severe acute illness with or without fever"
},


  {"id" : 1 ,
    "name" : "Tetanus, diphtheria, pertussis(Td:Tdap)",
    "indication" : "All people who lack written documentation of a primary series consisting of at least 3 doses of tetanus- and diphtheria-toxoid-containing vaccine" ,
    "administration":"Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs",
    "contrain":"- Previous severe allergic reaction<br> - For Tdap only, history of encephalopathy not attributable to an identifiable cause, within 7d following DTP/DTaP or Tdap"
  },


  {"id" : 2 ,
    "name" : "Pneumococcal conjugate (PCV13)",
    "indication" : "- Incidence of invasive pneumococcal disease (meningitis, sepsis) <b> is 35 times</b> higher in HIV-infected adults than in non-infected <br> <b>- As soon as possible>/b> to adults who are newly diagnosed with asymptomatic or symptomatic HIV infection" ,
    "administration":"HIV patients should first be given PCV13, followed by PPSV23 at least 8 weeks later. <br> If they are younger than age 65 years, they will need a second dose of PPSV23 at least 5 years after their initial dose and a third dose once they become age 65 years. <br> If they are age 65 years or older when first diagnosed, they will need only one dose",
    "contrain":"- Previous severe allergic reaction to this vaccine, including (for PCV13) to any diphtheria toxoid-containing vaccine, or to any of its components<br> - Moderate or severe acute illness"
  },


  {"id" : 3 ,
    "name" : "Pneumococcal polysaccharide(PPSV23)",
    "indication" : "- Incidence of invasive pneumococcal disease (meningitis, sepsis) <b> is 35 times</b> higher in HIV-infected adults than in non-infected <br> <b>- As soon as possible>/b> to adults who are newly diagnosed with asymptomatic or symptomatic HIV infection" ,
    "administration":"HIV patients should first be given PCV13, followed by PPSV23 at least 8 weeks later. <br> If they are younger than age 65 years, they will need a second dose of PPSV23 at least 5 years after their initial dose and a third dose once they become age 65 years. <br> If they are age 65 years or older when first diagnosed, they will need only one dose",
    "contrain":"- Previous severe allergic reaction to this vaccine, including (for PCV13) to any diphtheria toxoid-containing vaccine, or to any of its components<br> - Moderate or severe acute illness"
  },

  {"id" : 4 ,
    "name" : "Hepatitis A (HepA) IM",
    "indication" : "Adults seeking protection from (HAV) infection and persons with other risk factors (e.g., traveling to countries with high or intermediate rates, have ch. Liver dis or clotting factor disorders, illicit drug users, post exposure prophylaxis)" ,
    "administration":"2 dose schedule with a minimum of 6 month interval",
    "contrain":""
  },

  {"id" : 5 ,
    "name" : "Hepatitis B (HepB) IM",
    "indication" : "For all HIV positive persons " ,
    "administration":"3-dose series at 0, 1 and 6 month intervals(the 2<small><sup>nd</small></sup> should be at least 4 wks after the 1<small><sup>st</small></sup> and the 3<small><sup>rd</small></sup> should be at least 8 wks after the 2<small><sup>nd</small></sup> and at least 16 wks after the 1<small><sup>st</small></sup>)",
    "contrain":"- Previous severe allergic reaction<br> - Moderate or severe acute illness"
  },

  {"id" : 6 ,
    "name" : "Humanpapilloma virus (HPV)",
    "indication" : "For unvaccinated females, 13 through age 26yrs: Complete a 3-dose series of HPV2 or HPV4 <br> For unvaccinated males, 13 through age 21yrs: Complete a 3-dose series of HPV4 Males 22-26yrs may be vaccinated" ,
    "administration":"- 3 doses on a 0, 1–2, 6m schedule. Use either HPV2 or HPV4 for women, and only HPV4 for men <br> - Must be at least 4wks between doses #1 and #2 and at least 12wks between doses #2 and #3 ",
    "contrain":"- Previous severe allergic reaction <br> - Moderate or severe acute illness<br> - Pregnancy"
  },


  {"id" : 7 ,
    "name" : "MMR (Measles, Mumps, Rubella)",
    "indication" : "HIV patients who were born in 1957 or later & not severely immunocompromised (CD4+ T-lymphocyte counts are ≥ 200 cells/μL) if they have no laboratory evidence of immunity to each of the 3 diseases" ,
    "administration":"2 doses <br> dose #2 should be given at lease 4weeks  after dose #1",
    "contrain":"- Previous severe allergic reaction <br> - Pregnancy or possibility of pregnancy within 4wks<br> - Severe immunodeficiency<br> - History of thrombocytopenia or thrombocytopenic purpura"
  },


  {"id" : 8 ,
    "name" : "Varicella (Chickenpox)",
    "indication" : "- HIV patients who are not severely immunocompromised (CD4+ T-lymphocyte counts are ≥ to 200 cells/μL) without evidence of immunity to varicella<small><sup>*</small></sup> " ,
    "administration":"- 2 doses <br> - Dose #2 is given 4—8wks after dose #1.<br> - If dose #2 is delayed, do not repeat dose #1. Just give dose #2.",
    "contrain":"- Previous severe allergic reaction (e.g. anaphylaxis) <br> - Pregnancy<br> - Long-term immunosuppressive therapy or immunocompromised because of malignancy <br> - Receipt of specific antivirals - Moderate or severe acute illness"
  }]
,"icon" : "sec3logo"
,"name" : "HIV"
,"ref" : "*Evidence of immunity to varicella in adults includes any of the following:<br>- Documentation of 2 doses of varicella vaccine at least 4 weeks apart;<br>- History of varicella based on diagnosis or verification of varicella disease by a health care provider;<br>- History of herpes zoster based on diagnosis or verification of herpes zoster disease by a health care provider; <br>- Laboratory evidence of immunity or laboratory confirmation of disease.<br>1- Centers for Disease Control and Prevention. Department of Health and Human Services<br>2- Summary of Recommendations for Adult Immunization (Age 19 years and older). Centers for Disease Control and Prevention. 2015<br>3- National Foundation for Infectious Diseases. Available at: http://www.adultvaccination.org/professional-resources/pneumo/hiv.pdf"
,"bg" : "sec3bg"
,"btnBg" : "sec3btnbg"
,"textColor" : "sec3color"
}
